Alzheimer's disease remains one of the most pressing challenges in neurology today. It affects millions of people worldwide and significantly burdens healthcare systems, not only financially. As the population ages, so does the need for effective treatments. However, despite decades of research, most approved drugs treat symptoms rather than the underlying pathology of the disease. Recent developments offer new hope! The first drug to treat the disease has been approved in the US. The drug's European approval was renewed in February with a favorable recommendation. Where does Slovakia stand? How do we currently take care of patients with this diagnosis? Will we be able to provide them with adequate treatment? What obstacles do we have to overcome?